CRBU
Price
$1.53
Change
-$0.01 (-0.65%)
Updated
Jan 17 closing price
Capitalization
138.55M
65 days until earnings call
FATE
Price
$1.27
Change
+$0.02 (+1.60%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
144.65M
44 days until earnings call
Ad is loading...

CRBU vs FATE

Header iconCRBU vs FATE Comparison
Open Charts CRBU vs FATEBanner chart's image
Caribou Biosciences
Price$1.53
Change-$0.01 (-0.65%)
Volume$1.03M
Capitalization138.55M
Fate Therapeutics
Price$1.27
Change+$0.02 (+1.60%)
Volume$6.87K
Capitalization144.65M
CRBU vs FATE Comparison Chart
Loading...
CRBU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRBU vs. FATE commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRBU is a Hold and FATE is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (CRBU: $1.54 vs. FATE: $1.25)
Brand notoriety: CRBU and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRBU: 57% vs. FATE: 43%
Market capitalization -- CRBU: $138.55M vs. FATE: $144.65M
CRBU [@Biotechnology] is valued at $138.55M. FATE’s [@Biotechnology] market capitalization is $144.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRBU’s FA Score shows that 1 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • CRBU’s FA Score: 1 green, 4 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both CRBU and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRBU’s TA Score shows that 3 TA indicator(s) are bullish while FATE’s TA Score has 4 bullish TA indicator(s).

  • CRBU’s TA Score: 3 bullish, 4 bearish.
  • FATE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than CRBU.

Price Growth

CRBU (@Biotechnology) experienced а -10.47% price change this week, while FATE (@Biotechnology) price change was -25.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.05%. For the same industry, the average monthly price growth was +3.04%, and the average quarterly price growth was -1.59%.

Reported Earning Dates

CRBU is expected to report earnings on May 13, 2025.

FATE is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($145M) and CRBU($139M) have the same market capitalization . CRBU YTD gains are higher at: -3.145 vs. FATE (-24.242). CRBU has higher annual earnings (EBITDA): -161.7M vs. FATE (-177.57M). FATE has more cash in the bank: 297M vs. CRBU (228M). CRBU has less debt than FATE: CRBU (26.6M) vs FATE (99M). FATE has higher revenues than CRBU: FATE (13.4M) vs CRBU (11.5M).
CRBUFATECRBU / FATE
Capitalization139M145M96%
EBITDA-161.7M-177.57M91%
Gain YTD-3.145-24.24213%
P/E RatioN/AN/A-
Revenue11.5M13.4M86%
Total Cash228M297M77%
Total Debt26.6M99M27%
FUNDAMENTALS RATINGS
FATE: Fundamental Ratings
FATE
OUTLOOK RATING
1..100
65
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
97
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRBUFATE
RSI
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
79%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
86%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
81%
Bullish Trend 12 days ago
86%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 4 days ago
81%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Ad is loading...
CRBU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY591.64-1.14
-0.19%
SPDR® S&P 500® ETF Trust
BTC.X99756.910000-747.585940
-0.74%
Bitcoin cryptocurrency
GME27.72-0.24
-0.86%
GameStop Corp
TSLA413.82-14.40
-3.36%
Tesla
AAPL228.26-9.61
-4.04%
Apple

CRBU and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRBU has been loosely correlated with ALLO. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if CRBU jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRBU
1D Price
Change %
CRBU100%
-1.91%
ALLO - CRBU
55%
Loosely correlated
-1.60%
FATE - CRBU
50%
Loosely correlated
-5.30%
BEAM - CRBU
50%
Loosely correlated
+0.04%
ARVN - CRBU
50%
Loosely correlated
-0.85%
CRSP - CRBU
50%
Loosely correlated
+3.23%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-5.30%
ALLO - FATE
59%
Loosely correlated
-1.60%
NTLA - FATE
51%
Loosely correlated
-2.99%
CRSP - FATE
51%
Loosely correlated
+3.23%
CRBU - FATE
50%
Loosely correlated
-1.91%
RCKT - FATE
50%
Loosely correlated
-6.16%
More